HC Wainwright Has Lowered Expectations for vTv Therapeutics (NASDAQ:VTVT) Stock Price

vTv Therapeutics (NASDAQ:VTVT) had its price target cut by equities research analysts at HC Wainwright from $45.00 to $42.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 21.56% from the stock’s previous close.

Several other research firms have also weighed in on VTVT. Zacks Research lowered vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Weiss Ratings raised shares of vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Monday, May 18th. Rodman & Renshaw started coverage on shares of vTv Therapeutics in a report on Tuesday, June 30th. They issued a “buy” rating and a $67.00 price target for the company. BTIG Research increased their price objective on shares of vTv Therapeutics from $49.00 to $57.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. Finally, Wall Street Zen upgraded shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $55.83.

vTv Therapeutics Stock Up 0.5%

NASDAQ VTVT traded up $0.16 during trading on Thursday, reaching $34.55. 80,552 shares of the stock traded hands, compared to its average volume of 54,651. vTv Therapeutics has a fifty-two week low of $14.00 and a fifty-two week high of $44.00. The firm has a market cap of $136.09 million, a price-to-earnings ratio of -36.81 and a beta of 0.28. The stock’s 50-day moving average price is $33.34 and its 200 day moving average price is $34.80.

vTv Therapeutics (NASDAQ:VTVT) last posted its earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.08). Analysts anticipate that vTv Therapeutics will post -2.19 EPS for the current fiscal year.

Institutional Trading of vTv Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in VTVT. Geode Capital Management LLC lifted its position in shares of vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after purchasing an additional 12,896 shares in the last quarter. 683 Capital Management LLC bought a new position in vTv Therapeutics in the fourth quarter valued at $731,000. Finally, Goldman Sachs Group Inc. acquired a new stake in vTv Therapeutics in the 4th quarter valued at $221,000. 17.51% of the stock is currently owned by institutional investors and hedge funds.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.